All AbMole products are for research use only, cannot be used for human consumption.
In vitro: AZD9496 showed pmol/L equipotent binding to both ERα and ERβ isoforms. AZD9496 directly targets ERα for downregulation in vitro. And it also antagonizes and downregulates mutant ER in vitro and in vivo. The IC50s of ERα binding, ERα downregulation, ERα antagonism for AZD9496 are 0.82, 0.14 and 0.28 nM, respectively.
In vivo: AZD9496 showed high oral bioavailability across three species (F% 63, 91, and 74, rat, mouse, and dog, respectively) with generally low volume and clearance across species, albeit a higher clearance in mouse. The percent free levels in human plasma of 0.15% were 5-fold higher than those measured for fulvestrant. AZD9496 is a potent, oral inhibitor of breast tumor growth in vivo. AZD9496 causes tumor regressions in combination with PI3K pathway and CDK4/6 inhibitors and in an estrogen-deprived ER+ model of resistance. This effect was accompanied by a dose-dependent decrease in PR protein levels. AZD9496 is currently being evaluated in a phase I clinical trial.
| Cell Experiment | |
|---|---|
| Cell lines | MCF-7 cells |
| Preparation method | Cells were grown in steroid-free conditions in SILAC media containing 13C615N4 L-arginine to label ERα peptide as "heavy" and then switched to grow in media containing unlabeled l-arginine to label newly synthesized protein as "normal" with 0.1% DMSO, 300 nmol/L tamoxifen, 100 nmol/L AZD9496, or 100 nmol/L fulvestrant for the time indicated. |
| Concentrations | 100 nM |
| Incubation time | 0, 10, 20, 30, 40, 50 h |
| Animal Experiment | |
|---|---|
| Animal models | Sexually immature female Han Wistar rats |
| Formulation | PEG/Captisol |
| Dosages | 5 and 25 mg/kg once daily |
| Administration | oral gavage |
| Molecular Weight | 442.47 |
| Formula | C25H25F3N2O2 |
| CAS Number | 1639042-08-2 |
| Solubility (25°C) | 88 mg/mL in DMSO |
| Storage | 4°C, protect from light |
| Related Estrogen Receptor Products |
|---|
| GDC-0927
GDC-0927 (SRN-927) is a novel, potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist. |
| AC-186
AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. |
| Idoxifene
Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM). |
| (R)-Equol
(R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively. |
| (Rac)-Vepdegestrant
(Rac)-Vepdegestrant is the isomer of Vepdegestrant. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
